"We are thrilled to report these results." Patrick Ott, MD, PhD, director of the Center for Cancer Vaccines at Dana-Farber, and Derin Keskin, PhD, immunologist at the Center for Cancer Vaccines at ...

An experimental vaccine for kidney cancer is off to a promising start. In data from a Phase I trial released this week, the vaccine candidate appeared to be safe and produced a clear immune ...

A new personalized immunotherapy treatment called a cancer vaccine has shown promising results in a phase I trial in people with kidney cancer. The results from nine patients treated at Dana ...

Personalized cancer vaccines showed significant immune responses in stage III/IV renal cell carcinoma patients, with T-cells increasing 166-fold and persisting for up to three years. The vaccine ...

The crosstalk between autophagy and the cGAS-STING pathway impacts a wide variety of cellular processes such as protection against pathogenic infections as well as signaling in neurodegenerative ...

In a small clinical trial of nine patients with advanced kidney cancer, a personalized vaccine generated robust immune response. All patients remained cancer-free for an average of 3 years. The ...

THURSDAY, Feb. 6, 2025 (HealthDay News) -- A small, early trial of a vaccine that mobilizes the immune system to battle advanced kidney cancers appears successful, researchers report. The ...

The global fight against cancer is at a pivotal moment. A breakthrough in Russia promises to redefine cancer treatment, with the country announcing its first mRNA cancer vaccine. This revolutionary ...

Nine patients with advanced kidney cancer who received an experimental vaccine tailored to their tumors’ specific mutations mounted an immune response to their disease and remained cancer-free ...

Oncology vaccines have a wide potential to treat various kinds of cancer, even Vaccitech’s VTP-600 candidate going through clinical trials in lung cancer could potentially be repurposed to focus ...

BOSTON — In a remarkable advancement for cancer immunotherapy, researchers at Dana-Farber Cancer Institute have developed personalized vaccines that successfully triggered immune responses in all nine ...

mRNA specialist BioNTech has chalked up an important win in its cancer pipeline, showing efficacy with its BNT111 vaccine candidate in a phase 2 trial in advanced melanoma. The study is looking at ...